From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives

Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling domain of a TCR and co-stimulatory molecules. Its s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elisaveta Voynova, Damian Kovalovsky
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	HSCT T-cell CAR-T TIL cancer Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/1471f5ef444d4ee091b20c4a9d5d1c72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1471f5ef444d4ee091b20c4a9d5d1c72
record_format	dspace
spelling	oai:doaj.org-article:1471f5ef444d4ee091b20c4a9d5d1c722021-11-25T17:07:52ZFrom Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives10.3390/cells101128452073-4409https://doaj.org/article/1471f5ef444d4ee091b20c4a9d5d1c722021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2845https://doaj.org/toc/2073-4409Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling domain of a TCR and co-stimulatory molecules. Its success and approval by the U.S. Food and Drug Administration for the treatment of B-cell malignancies revolutionized the immunotherapy field, leading to extensive research on its possible application for other cancer types. In this review, we will focus on the evolution of CAR-T cell therapy outlining current technologies as well as major obstacles for its wide application. We will highlight achievements, the efforts to increase efficacy and to evolve into an off-the-shelf treatment, and as a possible future treatment for non-cancer related diseases.Elisaveta VoynovaDamian KovalovskyMDPI AGarticleHSCTT-cellCAR-TTILcancerBiology (General)QH301-705.5ENCells, Vol 10, Iss 2845, p 2845 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HSCT T-cell CAR-T TIL cancer Biology (General) QH301-705.5
spellingShingle	HSCT T-cell CAR-T TIL cancer Biology (General) QH301-705.5 Elisaveta Voynova Damian Kovalovsky From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
description	Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling domain of a TCR and co-stimulatory molecules. Its success and approval by the U.S. Food and Drug Administration for the treatment of B-cell malignancies revolutionized the immunotherapy field, leading to extensive research on its possible application for other cancer types. In this review, we will focus on the evolution of CAR-T cell therapy outlining current technologies as well as major obstacles for its wide application. We will highlight achievements, the efforts to increase efficacy and to evolve into an off-the-shelf treatment, and as a possible future treatment for non-cancer related diseases.
format	article
author	Elisaveta Voynova Damian Kovalovsky
author_facet	Elisaveta Voynova Damian Kovalovsky
author_sort	Elisaveta Voynova
title	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
title_short	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
title_full	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
title_fullStr	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
title_full_unstemmed	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives
title_sort	from hematopoietic stem cell transplantation to chimeric antigen receptor therapy: advances, limitations and future perspectives
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1471f5ef444d4ee091b20c4a9d5d1c72
work_keys_str_mv	AT elisavetavoynova fromhematopoieticstemcelltransplantationtochimericantigenreceptortherapyadvanceslimitationsandfutureperspectives AT damiankovalovsky fromhematopoieticstemcelltransplantationtochimericantigenreceptortherapyadvanceslimitationsandfutureperspectives
_version_	1718412696781586432

From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives

Ejemplares similares